At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GRAL GRAIL, Inc.
Market Closed 06-05 16:00:00 EDT
59.98
-6.57
-9.87%
盘后59.68
-0.30-0.50%
19:57 EDT
High65.53Low59.66Vol760.46K
Open63.99D1 Closing66.55Amplitude8.81%
Mkt Cap2.57BTradable Cap2.05BTotal Shares42.92M
T/O46.18MT/O Rate2.22%Tradable Shares34.19M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Grail (GRAL) Valuation Check As ASCO 2026 Galleri Data Lifts Early Cancer Detection Story
Simply Wall St.  ·  06-05 09:27
Grail (GRAL) Valuation Check As ASCO 2026 Galleri Data Lifts Early Cancer Detection Story
How GRAIL’s (GRAL) Galleri Trial Data Could Reframe Its Multi-Cancer Screening Investment Narrative
Simply Wall St.  ·  06-04 05:20
How GRAIL’s (GRAL) Galleri Trial Data Could Reframe Its Multi-Cancer Screening Investment Narrative
Grail files initial beneficial ownership statement for Chief Growth Officer Andrew Partridge
Reuters  ·  06-03
Grail files initial beneficial ownership statement for Chief Growth Officer Andrew Partridge
Piper Sandler Remains a Hold on GRAIL Inc (GRAL)
TIPRANKS  ·  06-02
Piper Sandler Remains a Hold on GRAIL Inc (GRAL)
Grail assumed with a Peer Perform at Wolfe Research
TIPRANKS  ·  06-02
Grail assumed with a Peer Perform at Wolfe Research
Sector Update: Healthcare Stocks Fall in Afternoon Trading
MT Newswires Live  ·  06-02
Sector Update: Healthcare Stocks Fall in Afternoon Trading
BUZZ-U.S. STOCKS ON THE MOVE-Grail, Kohl, Virgin Galactic
Reuters  ·  06-02
BUZZ-U.S. STOCKS ON THE MOVE-Grail, Kohl, Virgin Galactic
Grail falls -18.4%
TIPRANKS  ·  06-02
Grail falls -18.4%
BUZZ-Grail shares fall after large cancer blood test data yields mixed results
Reuters  ·  06-02
BUZZ-Grail shares fall after large cancer blood test data yields mixed results
Grail posts ASCO presentation on private-practice adoption of multi-cancer early detection test
Reuters  ·  06-01
Grail posts ASCO presentation on private-practice adoption of multi-cancer early detection test
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as AI Optimism Overshadows Middle East Risks
MT Newswires Live  ·  06-01
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as AI Optimism Overshadows Middle East Risks
GRAIL Shares Fall Pre-Bell After Galleri Trial Misses Primary Endpoint
MT Newswires Live  ·  06-01
GRAIL Shares Fall Pre-Bell After Galleri Trial Misses Primary Endpoint
Canaccord Genuity Keeps Their Buy Rating on GRAIL Inc (GRAL)
TIPRANKS  ·  06-01
Canaccord Genuity Keeps Their Buy Rating on GRAIL Inc (GRAL)
Grail's Galleri Test Improves Cancer Detection in Pathfinder 2 Trial
MT Newswires Live  ·  06-01
Grail's Galleri Test Improves Cancer Detection in Pathfinder 2 Trial
Grail presents ‘positive’ performance, safety results from Pathfinder 2 study
TIPRANKS  ·  06-01
Grail presents ‘positive’ performance, safety results from Pathfinder 2 study
Grail reports results from NHS-Galleri trial in presentation at ASCO meeting
TIPRANKS  ·  06-01
Grail reports results from NHS-Galleri trial in presentation at ASCO meeting
Grail Presents Pathfinder 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 Asco Annual Meeting
THOMSON REUTERS  ·  05-31
Grail Presents Pathfinder 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 Asco Annual Meeting
BRIEF-Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction In Stage Iv Cancer Diagnoses
Reuters  ·  05-30
BRIEF-Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction In Stage Iv Cancer Diagnoses
Grail - Galleri Blood Test Reduces Stage Iv Diagnoses by 22% in Second and 26% in Third Rounds
THOMSON REUTERS  ·  05-30
Grail - Galleri Blood Test Reduces Stage Iv Diagnoses by 22% in Second and 26% in Third Rounds
Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction in Stage Iv Cancer Diagnoses at 2026 Asco Annual Meeting
THOMSON REUTERS  ·  05-30
Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction in Stage Iv Cancer Diagnoses at 2026 Asco Annual Meeting

Introduction

Company Name.
GRAIL, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--